Literature DB >> 31378417

Multivariate analysis of prognostic factors in primary squamous cell vulvar cancer: The role of perineural invasion in recurrence and survival.

Federico Ferrari1, Sara Forte2, Laura Ardighieri3, Emma Bonetti2, Barbera Fernando4, Enrico Sartori2, Franco Odicino2.   

Abstract

OBJECTIVE: to assess the prognostic role in recurrence and survival of perineural invasion (PNI) in vulvar squamous cell cancer (VSCC).
METHODS: Patients underwent primary surgery for VSCC from January 2009 to December 2016 served as the study cohort. We collected demographic, clinical, pathological characteristics and follow-up data, and we compared them among PNI-negative versus -positivepatients. We calculated disease-free survival (DFS) and overall survival (OS) using Kaplan-Meier and univariate log-rank test. We conducted a multivariate analysis with cox-proportional hazard models for DFS and OS, including age, tumor size, depth of invasion, free tumor margin <8 mm, high-grade histology, lymph vascular space invasion, PNI, extracapsular lymph nodal disease, lymph nodal ratio >0.2 and FIGO Stage 2009 (Early I-II versus Advanced III-IV).
RESULTS: We found 74 patients with a PNI prevalence of 31.1%. The 5-year DFS was favourable for PNI-negative patients (72% versus 18%; p = 0.00). The 5-year OS was 75% versus 35% in favor of PNI-negative patients (p = 0.00). The subgroup analysis conducted among stage confirmed a decreased DFS and OS in PNI-positive patients. Multivariate analysis showed that PNI (HR 2.74; CI95% 1.10-7.13; p = 0.03) and extracapsular lymph nodal disease (HR 13.54; CI95% 2.87-64.07; p = 0.01) are independent prognostic factors for earlier recurrence. OS was significantly reduced in case of PNI (HR 4.93; CI95% 1.33-18.35; p = 0.01) and extracapsular lymph nodal disease (HR 10.63; CI95% 1.65-68.57; p = 0.01).
CONCLUSIONS: PNI is an independent prognostic factor for aggressive behavior and unfavorable course in VSCC and should be considered in adjuvant treatment planning.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Perineural invasion; Recurrence; Squamous cell vulvar cancer; Survival

Mesh:

Year:  2019        PMID: 31378417     DOI: 10.1016/j.ejso.2019.07.029

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Perineural Invasion Correlates With Common Pathological Variables and Clinical Outcomes of Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Radical Surgery and Inguinal-femoral Lymphadenectomy.

Authors:  Angiolo Gadducci; Sabina Pistolesi; Stefania Cosio; Chiara Comunale; Antonio Fanucchi; Antonio Giuseppe Naccarato
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 2.  Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review.

Authors:  Fulvio Borella; Mario Preti; Luca Bertero; Giammarco Collemi; Isabella Castellano; Paola Cassoni; Stefano Cosma; Andrea Roberto Carosso; Federica Bevilacqua; Niccolò Gallio; Chiara Benedetto; Leonardo Micheletti
Journal:  Int J Mol Sci       Date:  2020-12-27       Impact factor: 5.923

3.  The potential risk of contralateral non-sentinel groin node metastasis in women with early primary vulvar cancer following unilateral sentinel node metastasis: a single center evaluation in University Hospital of Düsseldorf.

Authors:  Andreas Suhartoyo Winarno; Anne Mondal; Franca Christina Martignoni; Tanja Natascha Fehm; Monika Hampl
Journal:  BMC Womens Health       Date:  2021-01-12       Impact factor: 2.809

4.  Perineural Invasion in Vulvar Squamous-Cell Carcinoma Is an Independent Risk Factor for Cancer-Specific Survival, but Not for Locoregional Recurrence: Results from a Single Tertiary Referral Center.

Authors:  Leonardo Micheletti; Fulvio Borella; Mario Preti; Valentina Frau; Stefano Cosma; Sebastiana Privitera; Luca Bertero; Chiara Benedetto
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

5.  Pelvic Exenteration for the Treatment of Locally Advanced Vulvar Cancer in South West Wales.

Authors:  Ganiy Opeyemi Abdulrahman; Nagindra Das; Thipparajapura V Chandrasekaran; Umesh Khot; Peter J Drew; Pradeep Bose; Jessica N Vet; Nasima Tofazzal; Shaun Roberts; Kerryn Lutchman Singh
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

6.  VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients.

Authors:  Antonella Ravaggi; Angela Gambino; Federico Ferrari; Alessandro Olivari; Laura Zanotti; Chiara Romani; Laura Ardighieri; Paolo Antonelli; Giorgia Garganese; Daniela Gallo; Giovanni Scambia; Eliana Bignotti; Enrico Sartori; Stefano Calza; Franco Odicino
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

7.  The multistep process of vaginal cancer arising from deep infiltrating endometriosis: a case report.

Authors:  Jee Hyun Kim; Seung Hun Song; Gwangil Kim; Kyoung Ah Kim; Woo Ram Kim
Journal:  BMC Womens Health       Date:  2021-07-12       Impact factor: 2.809

Review 8.  Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology.

Authors:  Pavol Zubor; Yun Wang; Alena Liskova; Marek Samec; Lenka Koklesova; Zuzana Dankova; Anne Dørum; Karol Kajo; Dana Dvorska; Vincent Lucansky; Bibiana Malicherova; Ivana Kasubova; Jan Bujnak; Milos Mlyncek; Carlos Alberto Dussan; Peter Kubatka; Dietrich Büsselberg; Olga Golubnitschaja
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

9.  Impact of endometrial sampling technique and biopsy volume on the diagnostic accuracy of endometrial cancer.

Authors:  Federico Ferrari; Sara Forte; Giulia Arrigoni; Laura Ardighieri; Maria Consuelo Coppola; Federica Salinaro; Fabio Barra; Enrico Sartori; Franco Odicino
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.